Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Phase 3 Unknown 160 enrolled Beijing Friendship Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.

Timeline

Start: 2019-08-31
Primary completion: 2021-07-31
Completion: 2021-07-31

Publications

Pi Y, Wang J, Zhou H, Ye X, Sun X, Liu L, Pan X, Wang Z. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study. J Cancer Res Clin Oncol. 2023 Jul;149(7):3033-3041. doi: 10.1007/s00432-022-04157-0. Epub 2022 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	35 mg/m2	Intravenous
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous
Subject	Methylprednisolone	Other / unclassified	0.1 mg/kg	Intravenous

Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Summary

Timeline

Publications

Drugs

Indications